Ceapro Inc.
4046 RTF: 8308 - 114 Street
Edmonton
Alberta
T6G 2E1
Canada
Tel: 780-421-4555
Fax: 780-421-1320
Website: http://www.ceapro.com/
128 articles about Ceapro Inc.
-
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
3/23/2023
Ceapro Inc. announced that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.
-
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
3/8/2023
Ceapro Inc. (TSX-V: CZO;OTCQX: CRPOF) (“Ceapro” or the “Company”) announced today that the abstract titled “Application of Avena Sativa Derived Therapeutics β-Glucan and Avenanthramide Accelerate Wound Healing in Mice Via Angiogenic and Anti-inflammatory Mechanisms,” has been accepted for a presentation at the Annual Meeting of the Wound Healing Society (WHS) to be held at the National Harbor, MD Conference Center between April 26-29, 2023.
-
Ceapro to Present at the Virtual Investor 2023 Companies to Watch EventLive video webcast on Wednesday, January 18th at 3:00 PM ET
1/10/2023
Ceapro Inc. today announced that Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officer of Ceapro, will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 3:00 PM ET.
-
Ceapro Announces Grant of Stock Options - Jan 04, 2023
1/4/2023
Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced the granting of stock options to employees, officers and directors of the Company.
-
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
12/22/2022
Ceapro Inc. today announced it has received approval from Health Canada to initiate its Phase 1/2a study evaluating the safety, tolerability, bioavailabilty and efficacy of its pharmaceutical grade tablet of avenanthramide as a potential anti-inflammatory product.
-
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
11/9/2022
Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2022.
-
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
11/7/2022
Ceapro Inc. announced the signing of a license agreement with The Governors of the University of Alberta to use designated areas within Agri-Food Discovery Place to further scale up the Company’s disruptive Pressurized Gas eXpanded technology in preparation for commercial partnerships.
-
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
10/13/2022
Ceapro Inc. today announced positive results from its collaborative project led by Dr. Donna Vine, Professor at the Department of Agriculture, Food and Nutritional Science of University of Alberta.
-
Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
8/24/2022
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2022.
-
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis
8/11/2022
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced it has entered into an additional research project expanding on the ongoing collaboration with McMaster University to develop an inhalable immuno-therapeutic/-prophylactic for COVID-19-induced lung fibrosis.
-
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
8/9/2022
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that positive results from a collaborative project with University of Alberta researchers have been accepted for publication in The Journal of Supercritical Fluids.
-
Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer
7/12/2022
Ceapro Inc. announced the appointment of Sigrun Watson as its Chief Revenue Officer, responsible for corporate strategy development and execution across the Cosmeceutical and personal care brand business, as well as Ceapro’s expansion into the Nutraceutical and Pharmaceutical markets.
-
Ceapro Announces Results of 2022 Shareholders’ Meeting
6/7/2022
Ceapro Inc. announced that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 1, 2022 as per the following results:
-
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
5/23/2022
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, President and Chief Executive Officer , of Ceapro, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL.
-
Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update
5/18/2022
Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2022.
-
Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
5/13/2022
Ceapro Inc. announced that Bernhard Seifried, Ph.D., Ceapro’s Senior Director, Research & Technology, will give a keynote lecture titled, Aerogels & Composites: From Concept to Applications, at the 13th International Symposium on Supercritical Fluids being held May 15-18, 2022 in Montréal, Québec, Canada.
-
Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates in the Journal of CO2 Utilization
5/11/2022
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), announced today that results from a collaborative project with University of Alberta researchers have been accepted for publication in the Journal of CO2 Utilization in an article titled, “Drying of sodium alginate using Pressurized Gas eXpanded (PGX) liquid technology,” authored by Liu Z, Couto R., Seifried B, Yépez B, Moquin P and Temelli F.
-
Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors
4/19/2022
Ceapro Inc. today announced the appointment of Geneviève Foster to its Board of Directors.
-
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
4/13/2022
Ceapro Inc. announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
3/10/2022
Ceapro Inc. announced the signing of a long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.